Can anyone weigh in on how effective Rebirth is compared to Nolva in PCT and whether you would recommend it over Nolva?
A paper was published in 2013 titled "Comparison of tamoxifen with edible seaweed (Eucheuma cottonii L.) extract in suppressing breast tumor."
In the abstract it says (bold added by me):
The tropical edible red seaweed (Eucheuma cottonii L.) is rich in nutrients and polyphenolic compounds that may suppress cancer through its antioxidant and antiproliferative properties. The study reports on rat mammary tumor suppression and tissue antioxidant status modulation by E. cottonii ethanol extract (ECE). The effect of orally administered ECE (100 mg/kg body-weight) was compared with that of tamoxifen (10 mg/kg body-weight). Rat was induced to develop mammary tumor with subcutaneous injection of LA-7 cells (6 × 10(6) cells/rat). The ECE was more effective than tamoxifen in suppressing tumor growth (27%), improving tissues (plasma, liver, and kidney) malondialdehyde concentrations, superoxide dismutase activity and erythrocyte glutathione concentrations (P < 0.05). Unlike tamoxifen, the ECE displayed little toxicity to the liver and kidneys. The ECE exhibited strong anticancer effect with enzyme modulating properties, suggesting its potential as a suppressing agent for mammary gland tumor.
The amount of ECE was 10x Nolva, but easier on the liver and kidneys. This would seem to suggest that a Nolva 20/20/10/10 ED PCT could be replaced with ECE 200/200/100/100 ED PCT with better results.
A paper was published in 2013 titled "Comparison of tamoxifen with edible seaweed (Eucheuma cottonii L.) extract in suppressing breast tumor."
In the abstract it says (bold added by me):
The tropical edible red seaweed (Eucheuma cottonii L.) is rich in nutrients and polyphenolic compounds that may suppress cancer through its antioxidant and antiproliferative properties. The study reports on rat mammary tumor suppression and tissue antioxidant status modulation by E. cottonii ethanol extract (ECE). The effect of orally administered ECE (100 mg/kg body-weight) was compared with that of tamoxifen (10 mg/kg body-weight). Rat was induced to develop mammary tumor with subcutaneous injection of LA-7 cells (6 × 10(6) cells/rat). The ECE was more effective than tamoxifen in suppressing tumor growth (27%), improving tissues (plasma, liver, and kidney) malondialdehyde concentrations, superoxide dismutase activity and erythrocyte glutathione concentrations (P < 0.05). Unlike tamoxifen, the ECE displayed little toxicity to the liver and kidneys. The ECE exhibited strong anticancer effect with enzyme modulating properties, suggesting its potential as a suppressing agent for mammary gland tumor.
The amount of ECE was 10x Nolva, but easier on the liver and kidneys. This would seem to suggest that a Nolva 20/20/10/10 ED PCT could be replaced with ECE 200/200/100/100 ED PCT with better results.